PacBio Files 8-K on Financials
Ticker: PACB · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1299130
Sentiment: neutral
Topics: financial-condition, results-of-operations
Related Tickers: PACB
TL;DR
PACB filed an 8-K, standard financial update, no major news.
AI Summary
On February 13, 2025, Pacific Biosciences of California, Inc. (PACB) filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, with no specific new financial figures or material events detailed in the provided text. The report confirms the company's legal name, incorporation state (Delaware), and principal executive office location in Menlo Park, California.
Why It Matters
This 8-K filing serves as a routine update on Pacific Biosciences' financial condition and operations, providing transparency to investors about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial condition and results of operations, with no new material events or significant financial disclosures provided in the excerpt.
Key Players & Entities
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (company) — Registrant
- 0001299130-25-000033 (filing_id) — Accession Number
- February 13, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 1305 O'Brien Drive, Menlo Park, California 94025 (address) — Principal Executive Offices
- 650-521-8000 (phone_number) — Business Phone
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on February 13, 2025.
What is the exact legal name of the company filing this report?
The exact legal name of the company filing this report is Pacific Biosciences of California, Inc.
In which state is Pacific Biosciences of California, Inc. incorporated?
Pacific Biosciences of California, Inc. is incorporated in Delaware.
What is the address of the company's principal executive offices?
The address of the company's principal executive offices is 1305 O'Brien Drive, Menlo Park, California 94025.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-02-13 16:11:21
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market
Filing Documents
- pacb-20250213.htm (8-K) — 24KB
- pacb-ex991xearningsrelease.htm (EX-99.1) — 284KB
- 0001299130-25-000033.txt ( ) — 451KB
- pacb-20250213.xsd (EX-101.SCH) — 2KB
- pacb-20250213_lab.xml (EX-101.LAB) — 21KB
- pacb-20250213_pre.xml (EX-101.PRE) — 12KB
- pacb-20250213_htm.xml (XML) — 3KB
02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 13, 2025, Pacific Biosciences of California, Inc. (the "Company") announced its financial results for its fourth fiscal quarter and year ended December 31, 2024. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference. This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. 99.1 Press Release dated February 1 3 , 202 5 , titled "PacBio Announces Fourth Quarter and Fiscal Year 202 4 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Michele Farmer Michele Farmer Vice President and Chief Accounting Officer Date: February 13, 2025